Avalo Therapeutics SG&A Expense (TTM) Analysis

Avalo Therapeutics Inc (AVTX)

12.47 -0.73 (-5.53%) USD | NASDAQ | Jun 28, 16:00

12.47 0.00 (0.00%) After-Hours: 07:50

SG&A Expense (TTM) Chart

Historical SG&A Expense (TTM) Data

View and export this data back to 2014. Upgrade now.

Date	Value
March 31, 2024	10.79M
December 31, 2023	10.30M
September 30, 2023	10.58M
June 30, 2023	11.38M
March 31, 2023	11.74M
December 31, 2022	20.71M
September 30, 2022	23.73M
June 30, 2022	26.38M
March 31, 2022	31.00M
December 31, 2021	24.66M
September 30, 2021	23.29M
June 30, 2021	22.40M
March 31, 2021	21.75M
December 31, 2020	19.76M
September 30, 2020	18.16M
June 30, 2020	15.98M
March 31, 2020	11.89M
December 31, 2019	11.61M
September 30, 2019	5.925M

Date	Value
June 30, 2019	7.268M
March 31, 2019	9.685M
December 31, 2018	11.06M
September 30, 2018	17.31M
June 30, 2018	15.27M
March 31, 2018	11.62M
December 31, 2017	8.511M
September 30, 2017	6.015M
June 30, 2017	5.567M
March 31, 2017	5.764M
December 31, 2016	7.083M
September 30, 2016	7.913M
June 30, 2016	6.932M
March 31, 2016	6.311M
December 31, 2015	4.423M
September 30, 2015	4.072M
June 30, 2015	4.978M
March 31, 2015	4.757M
December 31, 2014	4.875M

SG&A Expense Definition

SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.

Read full definition.

SG&A Expense (TTM) Range, Past 5 Years

5.925M

Minimum

Sep 2019

31.00M

Maximum

Mar 2022

17.47M

Average

18.16M

Median

Sep 2020

SG&A Expense (TTM) Benchmarks